Gefitinib-based PROTAC 3
目录号: A19093
基于吉非替尼的PROTAC 3,通过连接体将EGFR结合元素与VHL配体连接,分别在HCC827(外显子19缺失)和H3255(L858R突变)细胞中诱导EGFR降解,其DC50s分别为11.7 nM和22.3 nM。
全国免运费, 顺丰次日达
重要通知:仅供研究使用。我们不向患者销售。
重要通知:仅供研究使用。我们不向患者销售。
Discription | Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively. | ||
---|---|---|---|
Targets |
|
目录号 | A19093 |
---|---|
分子式 | C47H57ClFN7O8S |
分子量 | 934.51 |
CAS号 | 2230821-27-7 |
SMILES | O=C([C@H]1N(C([C@@H](NC(CCOCCOCCCCCOC2=CC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=C2OC)=O)C(C)(C)C)=O)C[C@H](O)C1)NCC5=CC=C(C6=C(C)N=CS6)C=C5 |
储存条件 | Store lyophilized at -20ºC, keep desiccated. |
In vitro | DMSO | 92 mg/mL (98.44 mM) | |
Water | Insoluble | ||
Ethanol | 92 mg/mL (98.44 mM) | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 10.7 mL | 53.5 mL | 107.01 mL |
0.5 mM | 2.14 mL | 10.7 mL | 21.4 mL |
1 mM | 1.07 mL | 5.35 mL | 10.7 mL |
5 mM | 0.21 mL | 1.07 mL | 2.14 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2